JiaLi C. Huang

JiaLi C. Huang

Auto-generated profile, based on publicly available information

JiaLi C. Huang

Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2025 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
YQYiqun Amy Qu
Yiqun Amy Qu
JHJiaLi C. Huang
JiaLi C. Huang
ZWZiqi V. Wang
Ziqi V. Wang
AFAngela L. Ferguson
Angela L. Ferguson
JNJasmine Minh Hang Nguyen
Jasmine Minh Hang Nguyen
Mark GorrellMark Gorrell
Mark Gorrell
Tumours contain many fibroblasts, endothelial cells, and leukocytes that are emerging as therapeutic targets complementary to targeting genetically unstable cancer cells. Immunotherapies directed towards this tumour microenvironment (TME) are increasingly effective. Targeting the endothelium has shown success, particularly in hepatocellular carcinoma (HCC). Cancer-associated fibroblasts (CAFs) are also attracting novel nascent therapeutic approaches, and fibroblast activation protein (FAP), which is specific to activated mesenchyme, is prominent amongst CAF markers. This review places emphasis upon FAP, human HCC, and FAP-targeting approaches for therapeutic benefit, including FAP inhibitors, radioligand therapy, T cell and antibody-dependent cytotoxicity/immunotherapy, and FAP-activated prodrugs.